Amylin And Takeda Team Up In Obesity
This article was originally published in PharmAsia News
Executive Summary
Two potentially important mid-stage programs in the obesity research space are off the partnering table with the announcement Nov. 1 that Takeda and Amylin have teamed up to develop and commercialize several obesity candidates, including pramlintide/metreleptin and davalintide
You may also be interested in...
Takeda/Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
Development of a once-promising combination of pramlintide and metreleptin for obesity has been discontinued after a "commercial reassessment," U.S.-based Amylin Pharmaceuticals Inc. and Japan's Takeda Pharmaceutical Company Limited announced Aug. 4
Takeda/Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
Development of a once-promising combination of pramlintide and metreleptin for obesity has been discontinued after a "commercial reassessment," U.S.-based Amylin Pharmaceuticals Inc. and Japan's Takeda Pharmaceutical Company Limited announced Aug. 4
Takeda, Sanford-Burnham Ink Obesity Discovery Deal To Explore Non-CNS Options
Takeda Pharmaceutical Co. Ltd. and the Sanford-Burnham Medical Research Institute have formed a collaboration focused on identifying and validating new targets and pathways outside of the central nervous system for treating obesity